New treatment approach shows promise in reducing prostate cancer spread

An international phase 3 trial with McGill University involvement showed that adding darolutamide (Nubeqa) to standard androgen deprivation therapy extended time without disease spread and reduced prostate cancer deaths in very high-risk prostate cancer patients. The double-blind, placebo-controlled study enrolled 1,106 patients in six countries and also found fewer PSA rises. Interim results were presented at the Presidential Symposium of the ESMO Congress; further follow-up will assess whether benefits persist and translate into longer overall survival.